Harrow Inc., a leading North American eyecare pharmaceutical company, announced its financial results for the first quarter ended March 31, 2025. The company reported revenues of $47.8 million, marking a 38% increase compared to the $34.6 million recorded in the same period last year. VEVYE revenues specifically rose to $21.5 million, a 35% increase from $16.0 million in the fourth quarter of 2024. Despite these increases, Harrow reported a GAAP net loss of $17.8 million for the quarter. The company's adjusted EBITDA stood at a negative $2.0 million. Additionally, Harrow's cash flow from operations reached a record high of $19.7 million, with cash and cash equivalents totaling $66.7 million as of March 31, 2025. A significant development during this period was the mid-March launch of the _VEVYE ® Access for All_ program, which has contributed to accelerating market share capture and revenue growth. The company has encouraged stockholders to review more detailed information available in its letter to stockholders and corporate presentation posted on its website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.